1. Augmentation of antitubercular therapy with IFNγ in a patient with dominant partial IFNγ receptor 1 deficiency.
- Author
-
Takeda K, Kawai T, Nakazawa Y, Komuro H, Shoji K, Morita K, Katsuta T, Yamamoto M, Miyairi I, Ohya Y, Ishiguro A, and Onodera M
- Subjects
- Drug Therapy, Combination, Female, Gene Expression, Humans, Infant, Interferon-gamma therapeutic use, Interleukin-12 genetics, Interleukin-12 immunology, Isoniazid therapeutic use, Mycobacterium bovis immunology, Mycobacterium bovis pathogenicity, Osteomyelitis complications, Osteomyelitis immunology, Receptors, Interferon immunology, Rifampin therapeutic use, Tuberculosis, Lymph Node complications, Tuberculosis, Lymph Node immunology, Virus Diseases complications, Virus Diseases immunology, Antitubercular Agents therapeutic use, Osteomyelitis drug therapy, Receptors, Interferon deficiency, Tuberculosis, Lymph Node drug therapy, Virus Diseases drug therapy
- Abstract
Osteomyelitis due to Mycobacterium bovis Bacille Calmette-Guerin (BCG) often develops in patients with interferon-γ receptor 1 (IFNγR1) deficiency. In these patients, susceptibility appears to be caused by impaired interleukin-12- and IFNγ-mediated immunity. Here we report the case of a one-year-old girl with dominant partial IFNγR1 deficiency who suffered from lymphadenitis and multiple sites of osteomyelitis due to BCG infection. She was allergic to isoniazid and rifampicin--the prescribed standard treatment--and required prior desensitization therapy. She was subsequently treated with these drugs, but her symptoms did not improve. IFNγ therapy was added to the antitubercular therapy, increasing the serum level of IFNγ and leading to the resolution of the lymphadenitis and osteomyelitis. In conclusion, high dose IFNγ therapy in combination with antitubercular drugs led to resolution of BCG infection in a patient with dominant partial IFNγ deficiency., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF